scholarly journals Red Cell Lipid Peroxidation and Antioxidant System in Chronic Renal Failure Patients Treated with Recombinant Human Erythropoietin

Nephron ◽  
1992 ◽  
Vol 61 (2) ◽  
pp. 228-229 ◽  
Author(s):  
S. Bozfakioğlu ◽  
N. Alptekin ◽  
Ş. Seçkin ◽  
E. Ark ◽  
N. Koçak-Toker
Keyword(s):  
Lipid Peroxidation ◽  
Renal Failure ◽  
Chronic Renal Failure ◽  
Antioxidant System ◽  
Recombinant Human Erythropoietin ◽  
Red Cell ◽  
Cell Lipid ◽  
Human Erythropoietin

▾ Epoetin – an important advance

1992 ◽  
Vol 30 (8) ◽  
pp. 29.2-32
Keyword(s):  
Renal Failure ◽  
Recombinant Human Erythropoietin ◽  
Antibody Formation ◽  
Blood Transfusions ◽  
Red Cell ◽  
Important Advance ◽  
Human Erythropoietin ◽  
Cell Antibody ◽  
Erythropoietin Deficiency ◽  
Made In

Erythropoietin is the endogenous hormone controlling red blood cell production. Most is made in the kidneys; if they fail, erythropoietin levels fall and anaemia develops. Treatment of erythropoietin deficiency anaemia in patients with renal failure has depended on repeated blood transfusions. Despite transfusions most patients remain anaemic and in addition are exposed to the risks of transfusion, such as viral infection, iron overload and problems associated with red cell antibody formation. The erythropoietin gene has been cloned and recombinant human erythropoietin (rHuEPO) is now marketed under the generic name epoetin. In this article we discuss the use of epoetin to treat anaemia in patients with renal failure and other potentially responsive conditions.

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin

1990 ◽  
Vol 89 (4) ◽  
pp. 432-435 ◽  
Author(s):  
Alan J. Watson ◽  
Luis F. Gimenez ◽  
Sandra Cotton ◽  
Mackenzie Walser ◽  
Jerry L. Spivak
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document